Fig. 1

Individual and group average trajectories per clinical stage for the global IADL Z-scores. The trajectories show that, at the group level, there is no decline in amyloid-negative individuals, but it does appear to be present in the earliest AD stages, and it increases with each subsequent stage. A one-unit change in the Z-score represents one standard deviation in the amyloid-negative group